

EARLY WARNING REPORT
FILED PURSUANT TO
NATIONAL INSTRUMENT 62-103

1. Name and Address of offeror:

bioLytical Laboratories, Inc.
1108-13351 Commerce Parkway
Richmond, British Columbia, V6V 2X7

bioLytical Laboratories, Inc. is referred to as the "Securityholder".

2. Designation and number or principal amount of securities and the offeror's security holding percentage in the class of securities of which the offeror acquired ownership or control in the transaction or occurrence giving rise to the obligation to file the news release, and whether it was ownership or control that was acquired in those circumstances:

On June 11, 2015, the Securityholder and Network Oncology Inc. (the "**Company**") entered into a license agreement whereby the Company would issue 15,000,000 common shares (the "**Shares**") to the Securityholder at a price of \$0.10 per share. On June 16, 2015, the Company issued the Shares to the Securityholder, which represents approximately 18.6% of the issued and outstanding shares of the Company.

A news release in connection with the foregoing was issued by the Securityholder on June 18, 2015 and filed with Canadian securities regulatory authorities on the System for Electronic Document Analysis and Retrieval ("**SEDAR**") at www.sedar.com.

3. Designation and number or principal amount of securities and the offeror's security holding percentage in the class of securities immediately after the transaction or occurrence giving rise to the obligation to file the news release:

Other than the Shares acquired by the Securityholder, the Securityholder does not own or exercise control or direction over any Shares of securities convertible into Shares. As such, the Securityholder owns and controls 15,000,000 shares of the Company, which represents approximately 18.6% of the issued and outstanding shares of the Company.

4. Designation and number or principal amount of securities and the percentage of outstanding securities of the class of securities referred to in paragraph 3 over which:

(i) **the offeror, either alone or together with any joint actors, has ownership and control;**

See Item 2 and 3 above.

(ii) **the offeror, either alone or together with any joint actors, has ownership but control is held by other persons or companies other than the offeror or any joint actor; and**

Not applicable.

(iii) **the offeror, either alone or together with any joint actors, has exclusive or shared control but does not have ownership.**

Not applicable.

5. Name of the market in which the transaction or occurrence that gave rise to the report took place:

The Shares were issued directly by the Company to the Securityholder.

6. The value, in Canadian dollars, of any consideration offered per security if the offeror acquired ownership of a security in the transaction or occurrence giving rise to the obligation to file a news release:

CAD\$0.10 per share.

7. Purpose of the offeror and any joint actors in effecting the transaction or occurrence that gave rise to the news release, including any future intention to acquire ownership of, or control over, additional securities of the reporting issuer:

The Securityholder acquired the Shares for investment purposes. Depending on economic or market conditions or matters relating to the Company, the Securityholder may choose to either acquire additional common shares or dispose of common shares of the Company.

8. General nature and the material terms of any agreement, other than lending arrangements, with respect to securities of the reporting issuer entered into by the offeror, or any joint actor, and the issuer of the securities or any other entity in connection with the transaction or occurrence giving rise to the news release, including agreements with respect to the acquisition, holding, disposition or voting of any of the securities:

Not applicable.

9. Names of any joint actors in connection with the disclosure required by this report:

Not applicable.

10. In the case of a transaction or occurrence that did not take place on a stock exchange or other market that represents a published market for the securities, including an issuance from treasury, the nature and value of the consideration paid by the offeror.

See Item 6 above.

11. If applicable, a description of any change in any material fact set out in a previous report filed under the early warning requirements or Part 4 of Nation Instrument 62-103 in respect of the reporting issuer's securities:

Not applicable.

12. If applicable, a description of the exemption from securities legislation being relied on by the offeror and the facts supporting that reliance:

Not applicable.

Dated this 18th day of June, 2015

/s/ Robert Mackie

bioLytical Laboratories, Inc.